Melina Makatsori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melina Makatsori has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Gianenrico Senna
Department of Medicine, University of Verona, 37134 Verona, Italy
2 shared publications Moises A. Calderon
Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London, United Kingdom
2 shared publications- Moises A. Calderon
Section of Allergy and Clinical Immunology, Imperial College London, London, UK
2 shared publications - A L Manson
Department of Clinical Immunology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK
1 shared publication A. L. Manson
1 shared publicationB. Grimbacher
1 shared publication
Latest Publications
- 1 May 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (3) , 640-648
The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment
- 1 May 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (3) , 640-648
The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment
- Open Access
- 1 January 2015
- Published by Wiley in Clinical and Translational Allergy
- Vol. 5 (1) , 17
Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol
Background: Adherence to allergen immunotherapy is important for its effectiveness. There is currently limited data available on allergen immunotherapy adherence outside of clinical trials i.e. in real‐life clinical practice. As part of a European Academy of Allergy and Clinical Immunology Immunotherapy Interest group initiative, we endeavoured to design a survey in order to prospectively evaluate adherence to subcutaneous and sublingual immunotherapy across different European countries.Method/Design: The inclusion criteria for this prospective, multi‐country survey were set as: adults, starting clinically indicated allergen immunotherapy for respiratory allergic disorders or Hymenoptera venom allergy. An online survey was designed in order to enrol participants and assess adherence to immunotherapy.Eight countries (Czech Republic, Georgia, Germany, Greece, Italy, Poland, Portugal, Spain) were selected to reflect different parts of Europe and differences in allergens and routes of immunotherapy administration. Each country has an allocated National co‐ordinator that has identified local Allergy departments willing to enrol participants in this survey.Each participant will be followed up for a total of three years. In order to assess adherence, a 4‐monthly follow‐up form detailing any missed doses and reasons will be completed online. In case of a participant discontinuing treatment, reasons for this will be recorded.Discussion: The use of online survey software has enabled us to make this survey a reality and reach clinicians in different countries. Forty‐five centres have enrolled a total of over 1,350 participants. It is hoped that this prospective real life survey will enable us to gain a better understanding of reasons that affect adherence to subcutaneous and sublingual immunotherapy and assist in developing ways to improve this.
- 1 January 2015
- Published by Wiley in Clinical and Translational Allergy
- Vol. 5 (1) , 17
Open AccessProspective adherence to specific immunotherapy in Europe (PASTE) survey protocol
Background: Adherence to allergen immunotherapy is important for its effectiveness. There is currently limited data available on allergen immunotherapy adherence outside of clinical trials i.e. in real‐life clinical practice. As part of a European Academy of Allergy and Clinical Immunology Immunotherapy Interest group initiative, we endeavoured to design a survey in order to prospectively evaluate adherence to subcutaneous and sublingual immunotherapy across different European countries.Method/Design: The inclusion criteria for this prospective, multi‐country survey were set as: adults, starting clinically indicated allergen immunotherapy for respiratory allergic disorders or Hymenoptera venom allergy. An online survey was designed in order to enrol participants and assess adherence to immunotherapy.Eight countries (Czech Republic, Georgia, Germany, Greece, Italy, Poland, Portugal, Spain) were selected to reflect different parts of Europe and differences in allergens and routes of immunotherapy administration. Each country has an allocated National co‐ordinator that has identified local Allergy departments willing to enrol participants in this survey.Each participant will be followed up for a total of three years. In order to assess adherence, a 4‐monthly follow‐up form detailing any missed doses and reasons will be completed online. In case of a participant discontinuing treatment, reasons for this will be recorded.Discussion: The use of online survey software has enabled us to make this survey a reality and reach clinicians in different countries. Forty‐five centres have enrolled a total of over 1,350 participants. It is hoped that this prospective real life survey will enable us to gain a better understanding of reasons that affect adherence to subcutaneous and sublingual immunotherapy and assist in developing ways to improve this.
- 5 November 2014
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 10 (12) , 1641-1647
Sublingual allergen immunotherapy for respiratory allergies: what is new?
Sublingual immunotherapy (SLIT) is a disease-modifying treatment for respiratory allergies that has been used for many years in Europe and has also recently been approved for use in North America. Its use is thus likely to increase. There is more evidence available regarding SLIT efficacy and its good safety profile, making it an appealing treatment option. The majority of studies have mostly focused on grass pollens; however, there are now data available regarding efficacy for other allergens. This review will summarize recent findings from SLIT clinical trials for respiratory allergies, including efficacy, safety, post-discontinuation effects and use in different age groups. Grass pollen, tree pollen, house dust mite and ragweed SLIT studies will be evaluated.
- 5 November 2014
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 10 (12) , 1641-1647
Sublingual allergen immunotherapy for respiratory allergies: what is new?
Sublingual immunotherapy (SLIT) is a disease-modifying treatment for respiratory allergies that has been used for many years in Europe and has also recently been approved for use in North America. Its use is thus likely to increase. There is more evidence available regarding SLIT efficacy and its good safety profile, making it an appealing treatment option. The majority of studies have mostly focused on grass pollens; however, there are now data available regarding efficacy for other allergens. This review will summarize recent findings from SLIT clinical trials for respiratory allergies, including efficacy, safety, post-discontinuation effects and use in different age groups. Grass pollen, tree pollen, house dust mite and ragweed SLIT studies will be evaluated.
- 26 October 2014
- Published by Wiley in Contact Dermatitis
- Vol. 71 (5) , 314-315
Silk contact anaphylaxis
- 26 October 2014
- Published by Wiley in Contact Dermatitis
- Vol. 71 (5) , 314-315
Silk contact anaphylaxis
- Open Access
- 28 April 2014
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 107 (10) , 821-828
Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes
Background: Rituximab, a chimeric monoclonal antibody against CD20, is increasingly used in the treatment of B-cell lymphomas and autoimmune conditions. Transient peripheral B-cell depletion is expected following rituximab therapy. Although initial clinical trials did not show significant hypogammaglobulinaemia, reports of this are now appearing in the literature. Methods: We performed a retrospective review of patients previously treated with rituximab that were referred to Clinical Immunology with symptomatic or severe hypogammaglobulinaemia. Patient clinical histories, immunological markers, length of rituximab treatment and need for intravenous immunoglobulin replacement therapy (IVIG) were evaluated. An audit of patients receiving rituximab for any condition in a 12-month period and frequency of hypogammaglobulinaemia was also carried out. Results: We identified 19 post-rituximab patients with persistent, symptomatic panhypogammaglobulinaemia. Mean IgG level was 3.42 ± 0.4 g/l (normal range 5.8–16.3 g/l). All patients had reduced or absent B-cells. Haemophilus Influenzae B, tetanus and Pneumococcal serotype-specific antibody levels were all reduced and patients failed to mount an immune response post-vaccination. Nearly all of them ultimately required IVIG. The mean interval from the last rituximab dose and need for IVIG was 36 months (range 7 months–7 years). Of note, 23.7% of 114 patients included in the audit had hypogammaglobulinaemia. Conclusion: With the increasing use of rituximab, it is important for clinicians treating these patients to be aware of hypogammaglobulinaemia and serious infections occurring even years after completion of treatment and should be actively looked for during follow-up. Referral to clinical immunology services and, if indicated, initiation of IVIG should be considered.
- 28 April 2014
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 107 (10) , 821-828
Open AccessHypogammaglobulinaemia after rituximab treatment--incidence and outcomes
Background: Rituximab, a chimeric monoclonal antibody against CD20, is increasingly used in the treatment of B-cell lymphomas and autoimmune conditions. Transient peripheral B-cell depletion is expected following rituximab therapy. Although initial clinical trials did not show significant hypogammaglobulinaemia, reports of this are now appearing in the literature. Methods: We performed a retrospective review of patients previously treated with rituximab that were referred to Clinical Immunology with symptomatic or severe hypogammaglobulinaemia. Patient clinical histories, immunological markers, length of rituximab treatment and need for intravenous immunoglobulin replacement therapy (IVIG) were evaluated. An audit of patients receiving rituximab for any condition in a 12-month period and frequency of hypogammaglobulinaemia was also carried out. Results: We identified 19 post-rituximab patients with persistent, symptomatic panhypogammaglobulinaemia. Mean IgG level was 3.42 ± 0.4 g/l (normal range 5.8–16.3 g/l). All patients had reduced or absent B-cells. Haemophilus Influenzae B, tetanus and Pneumococcal serotype-specific antibody levels were all reduced and patients failed to mount an immune response post-vaccination. Nearly all of them ultimately required IVIG. The mean interval from the last rituximab dose and need for IVIG was 36 months (range 7 months–7 years). Of note, 23.7% of 114 patients included in the audit had hypogammaglobulinaemia. Conclusion: With the increasing use of rituximab, it is important for clinicians treating these patients to be aware of hypogammaglobulinaemia and serious infections occurring even years after completion of treatment and should be actively looked for during follow-up. Referral to clinical immunology services and, if indicated, initiation of IVIG should be considered.
- Open Access
Dropouts in sublingual allergen immunotherapy trials – a systematic review
Participant dropouts can reduce the power of allergen immunotherapy clinical trials. Evaluation of the dropout rate and reasons for dropout are important not only in the planning of clinical studies but are also relevant for adherence to immunotherapy in daily clinical practice. A systematic review was carried out in order to establish the overall dropout rate among published double‐blind, placebo‐controlled randomized clinical trials of sublingual immunotherapy for respiratory allergic diseases. Dropouts were analysed in regards to allergen, formulation, treatment schedule, participant age, study size, number of centres and type of allergic disease. Relative dropout rates in placebo and active groups as well as reasons for dropout were also assessed. A total of 81 studies, comprising 9998 patients, were included. Dropout rates in sublingual immunotherapy controlled studies do not appear to be a major problem with a composite dropout percentage of 14% (95% CI:11.9–16). Furthermore, they are not different for active compared to placebo‐treated participants. This lends support to the positive clinical outcomes seen in meta‐analyses of these trials.
Open AccessDropouts in sublingual allergen immunotherapy trials – a systematic review
Participant dropouts can reduce the power of allergen immunotherapy clinical trials. Evaluation of the dropout rate and reasons for dropout are important not only in the planning of clinical studies but are also relevant for adherence to immunotherapy in daily clinical practice. A systematic review was carried out in order to establish the overall dropout rate among published double‐blind, placebo‐controlled randomized clinical trials of sublingual immunotherapy for respiratory allergic diseases. Dropouts were analysed in regards to allergen, formulation, treatment schedule, participant age, study size, number of centres and type of allergic disease. Relative dropout rates in placebo and active groups as well as reasons for dropout were also assessed. A total of 81 studies, comprising 9998 patients, were included. Dropout rates in sublingual immunotherapy controlled studies do not appear to be a major problem with a composite dropout percentage of 14% (95% CI:11.9–16). Furthermore, they are not different for active compared to placebo‐treated participants. This lends support to the positive clinical outcomes seen in meta‐analyses of these trials.
- 9 January 2014
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 1 (1) , 27-38
Health-Related Quality of Life and Rhinitis Control Measures in Allergic Rhinitis
- 9 January 2014
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 1 (1) , 27-38
Health-Related Quality of Life and Rhinitis Control Measures in Allergic Rhinitis
- 1 May 2013
- Vol. 45 (3) , 111-2
Penile granulomatosis presenting as pseudoangioedema.
Many conditions may present as angioedema. We report a case of a 46 year-old man presenting with intermittent episodes of penile swelling. Following a series of investigations, he was diagnosed with genital granulomatosis. Ano-genital granulomatosis is a rare chronic inflammatory condition and that can present as diffuse penile, scrotal, vulvar or ano-perineal swelling with non-caseating non-necrotising granulomas on histology.
- 1 May 2013
- Vol. 45 (3) , 111-2
Penile granulomatosis presenting as pseudoangioedema.
Many conditions may present as angioedema. We report a case of a 46 year-old man presenting with intermittent episodes of penile swelling. Following a series of investigations, he was diagnosed with genital granulomatosis. Ano-genital granulomatosis is a rare chronic inflammatory condition and that can present as diffuse penile, scrotal, vulvar or ano-perineal swelling with non-caseating non-necrotising granulomas on histology.